First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

By Y. Wu, C. Zhou, C. Liam, G. Wu, X. Liu, Z. Zhong, S. Lu, Y. Cheng, B. Han, L. Chen and 12 more. Annals of Oncology, 2015

720 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/273fe0fc677ddf7bb7a22ffa3cdb7a6c4d4feb15

Citations in the corpus

• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2016, neutral): “Thrombocytopenia† 28 (10) 1 (<1) 27 (20) 10 (7)”
• Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer (2018, neutral): “Number of patients with CNS progression* 10 (19) 27 (43) 7 (3) 15 (7) Progression in CNS only 3 (6) 10 (16) 4 (2) 12 (6) New lesions only 3 (6) 9 (14) 4 (2) 12 (6) Non-target lesions only 0 0 0 0 New and non-target lesions 0 1 (2) 0 0 Progression in CNS and non-CNS 7 (13) 17 (27) 3 (1) 3 (1) New les”